Zealand Pharma AS logo

Zealand Pharma AS

0
OCSE:ZEAL (Denmark)  
kr 847.00 (+4.12%) Nov 8
At Loss
P/B:
6.47
Market Cap:
kr 59.84B ($ 8.60B)
Enterprise V:
kr 51.76B ($ 7.44B)
Volume:
259.07K
Avg Vol (2M):
184.12K
Trade In:
Volume:
259.07K
At Loss
Avg Vol (2M):
184.12K

Business Description

Description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Name Current Vs Industry Vs History
Cash-To-Debt 21.75
Equity-to-Asset 0.92
Debt-to-Equity 0.04
Debt-to-EBITDA -0.41
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 46.05
Distress
Grey
Safe
Beneish M-Score -1.21
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 57.5
9-Day RSI 56.24
14-Day RSI 54.41
6-1 Month Momentum % 22.21
12-1 Month Momentum % 177.07

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 35.49
Quick Ratio 35.49
Cash Ratio 34.49
Days Inventory 78.75
Days Sales Outstanding 469.3
Days Payable 4174.32

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -13.6
Shareholder Yield % -14.28

Financials (Next Earnings Date:2025-02-27 Est.)

OCSE:ZEAL's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Zealand Pharma AS Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 76.87
EPS (TTM) (kr) -16.75
Beta 1.02
Volatility % 59.84
14-Day RSI 54.41
14-Day ATR (kr) 37.072012
20-Day SMA (kr) 818.625
12-1 Month Momentum % 177.07
52-Week Range (kr) 274.4 - 972
Shares Outstanding (Mil) 70.65

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Zealand Pharma AS Filings

Filing Date Document Date Form
No Filing Data

Zealand Pharma AS Stock Events

Financials Calendars
Event Date Price(kr)
No Event Data

Zealand Pharma AS Frequently Asked Questions

What is Zealand Pharma AS(OCSE:ZEAL)'s stock price today?
The current price of OCSE:ZEAL is kr847.00. The 52 week high of OCSE:ZEAL is kr972.00 and 52 week low is kr274.40.
When is next earnings date of Zealand Pharma AS(OCSE:ZEAL)?
The next earnings date of Zealand Pharma AS(OCSE:ZEAL) is 2025-02-27 Est..
Does Zealand Pharma AS(OCSE:ZEAL) pay dividends? If so, how much?
Zealand Pharma AS(OCSE:ZEAL) does not pay dividend.

Press Release

Subject Date
No Press Release